Biomarkers Consortium

Young research scientists


Q&A with George H. Talbot

FNIH Biomarkers Consortium and Critical Path Institute achieve the first ever qualification of a clinical safety biomarker by the U.S. Food and Drug Administration.

Q&A with George H. Talbot

In this Q&A, George H. Talbot, M.D., HABP/VABP Project Principal Investigator and Project Team Co-Chair, discusses the project’s history and significant achievements to-date that will help design more efficient clinical trials and facilitate the antibiotic approval process.

Lawrence Schwartz

This FNIH Biomarkers Consortium project will seek regulatory qualification of new biomarkers that predict the change in joint damage over time from knee osteoarthritis.

The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.

The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.

Front Page: